Orphalan v. Novitium Pharma: CUVRIOR® Patent Action Voluntarily Dismissed
Orphalan SA, holder of two patents covering trientine tetrachloride (CUVRIOR®) tablets, filed suit against generic manufacturer Novitium Pharma LLC in the District of Delaware. The infringement action was voluntarily dismissed without prejudice just 63 days after filing, before Novitium served any answer or dispositive motion.
CUVRIOR® Patent Suit Ends Before Novitium Files Any Response
On September 29, 2023, Orphalan SA — a specialty pharmaceutical company and holder of US10988436B2 and US11072577B2 covering trientine tetrachloride formulations — filed a patent infringement action against Novitium Pharma LLC in the United States District Court for the District of Delaware, case no. 1:23-cv-01079, before Judge Gregory B. Williams. The asserted patents relate to CUVRIOR® tablets (trientine tetrachloride, 300 mg), a treatment for Wilson's disease, and the suit was directed at Novitium's generic trientine tetrachloride tablets, 300 mg.
The recorded basis of termination is Voluntary dismissal. The docket order states that Orphalan, by its attorneys at McCarter & English LLP, filed a notice of voluntary dismissal without prejudice pursuant to Federal Rule of Civil Procedure 41(a)(1)(A), on the basis that Novitium had not yet served an answer or dispositive motion, making such dismissal procedurally available as of right. The case was closed on December 1, 2023.
The case resolved in just 63 days — an unusually short window that predates any substantive engagement by Novitium on the merits. Because the dismissal was without prejudice, Orphalan retains the right to re-file. What drove the early dismissal — whether driven by strategic recalibration, licensing discussions, or other commercial considerations — is not disclosed in the available public record. Novitium's patent position and any response it may have prepared also remain unknown from the public record.
See Complete Case & Patent Analysis →Filing to Voluntary dismissal in 63 days
Case resolved in 63 days — well before any substantive motion practice commenced.
US10988436B2 & US11072577B2 — Trientine Tetrachloride (CUVRIOR®) Tablets
Any company developing, manufacturing, or seeking regulatory approval for a generic or biosimilar trientine tetrachloride tablet product — particularly at the 300 mg dosage form — should treat both US10988436B2 and US11072577B2 as live enforcement risks. This case demonstrates that Orphalan is prepared to litigate in Delaware at the first indication of generic market entry. The voluntary dismissal without prejudice means neither patent has been adjudicated and both remain fully enforceable.
Official order — verbatim text
The voluntary dismissal notice invokes Rule 41(a)(1)(A) — the procedural right available to a plaintiff before any responsive pleading is served. The order confirms no merits ruling was made and the dismissal is expressly without prejudice. For Orphalan, this preserves all patent claims intact; for Novitium, it means no judgment in its favour and continued exposure to re-assertion of US10988436B2 and US11072577B2.
Voluntarily dismissed: what the Rule 41 exit means for both parties
Rule 41(a)(1)(A): dismissal as of right, without prejudice
Under Federal Rule of Civil Procedure 41(a)(1)(A), a plaintiff may voluntarily dismiss an action without a court order before the defendant has served an answer or motion for summary judgment. Because Novitium had not yet responded, Orphalan could exit the litigation unilaterally. A dismissal without prejudice means the action is terminated but no judgment on the merits is entered — the claims survive for potential re-filing.
No merits adjudicationWithout prejudice: what the record says and what it doesn't
The docket expressly records this as a voluntary dismissal without prejudice, meaning Orphalan is not barred from asserting the same patents against Novitium again. A dismissal with prejudice would have extinguished those rights permanently. The public record is silent on whether any conditions, commitments, or agreements between the parties accompanied this dismissal — the specific terms, if any exist, are not disclosed in the available record.
Re-filing rights preservedNovitium exits without a judgment — but the risk is not extinguished
Novitium Pharma faces no adverse court judgment from this action. No answer, invalidity argument, or dispositive motion appears in the public record. However, because the dismissal is without prejudice, Novitium cannot treat this litigation as a final resolution of Orphalan's patent claims against its trientine tetrachloride product. The two asserted patents remain in force and Orphalan retains enforcement rights.
No judgment against NovitiumGeneric trientine tetrachloride entry remains legally contested
The early voluntary dismissal without prejudice suggests the patent dispute over generic trientine tetrachloride (CUVRIOR®) is unresolved rather than concluded. Other generic entrants or ANDA filers in the Wilson's disease treatment space should note that US10988436B2 and US11072577B2 remain active and enforceable. The commercial calculus for any party considering generic entry into the trientine tetrachloride market is not materially altered by this dismissal alone.
Patents remain enforceableFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Orphalan, SA | Company | /Search in Eureka ↗ |
| Defendant | Novitium Pharma, LLC | Company | /Search in Eureka ↗ |
| Plaintiff counsel | Alexandra M. Joyce | Attorney | Counsel for Orphalan, SASearch in Eureka ↗ |
| Plaintiff counsel | Daniel M. Silver | Attorney | Counsel for Orphalan, SASearch in Eureka ↗ |
| Plaintiff law firm | McCarter & English LLP | Law Firm | Representing Orphalan, SASearch in Eureka ↗ |
| Presiding judge | Judge Gregory B. Williams | Judge | Delaware District CourtSearch in Eureka ↗ |
R&D signals in the trientine tetrachloride and Wilson's disease IP space
Forward-looking patent intelligence on CUVRIOR®, Orphalan's filing activity, and the competitive landscape for trientine-based Wilson's disease therapies.
Orphalan's trientine tetrachloride filing activity beyond this case
Orphalan asserted two distinct US patents — US10988436B2 and US11072577B2 — suggesting a layered filing strategy around CUVRIOR®. Investigating Orphalan's broader portfolio, including any pending continuations, divisionals, or foreign counterparts, reveals the full perimeter of exclusivity that generic developers must navigate in the Wilson's disease treatment space.
Portfolio depth signalFiling trends in copper chelation therapy formulations
Trientine tetrachloride sits within the broader copper chelation therapy landscape. Patent filing activity around trientine salts, formulation improvements, and Wilson's disease drug delivery has grown with increasing regulatory interest in rare metabolic disorders. Mapping these trends can identify which technical approaches are now crowded and where white space remains for next-generation formulations.
Copper chelation filing trendsNovitium Pharma's patent and ANDA activity in specialty generics
Novitium Pharma is an active participant in the US specialty generics market. Reviewing its patent portfolio, ANDA filing history, and any paragraph IV certifications in the rare-disease or orphan-drug space provides context for how it typically approaches branded-generic patent disputes — and whether trientine tetrachloride remains a target for its pipeline.
Generic competitor postureAdjacent innovation opportunities near trientine tetrachloride patents
The asserted patents cover specific trientine tetrachloride formulations and dosage forms. Adjacent areas — including alternative copper chelation mechanisms, novel trientine salt forms, paediatric formulations, or combination therapies for Wilson's disease — may represent less-crowded IP territory. Identifying these gaps can guide R&D investment decisions for companies entering the rare metabolic disease space.
Rare disease white spaceSimilar pharmaceutical patent cases in Delaware District Court
Explore related ANDA and rare-disease pharmaceutical patent infringement cases filed in the District of Delaware involving small-molecule formulation patents.
What this case signals for the trientine tetrachloride IP landscape
A fast voluntary dismissal before any defense response raises questions generic entrants in the Wilson's disease space cannot ignore.
Without-prejudice exit keeps Orphalan's enforcement options open
Orphalan's Rule 41(a)(1)(A) dismissal carries no admission, no judgment, and no estoppel. For generic manufacturers in the trientine tetrachloride space, this is not a clearance event. Both US10988436B2 and US11072577B2 remain in force and can be asserted again — against Novitium or any other party — without the barrier of claim preclusion.
Speed of dismissal is itself a commercial signal worth monitoring
A 63-day life span — from filing to dismissal before any answer — is consistent with cases where early-stage commercial discussions shift the litigation calculus. The public record does not confirm or deny any such development. IP teams tracking CUVRIOR® market entry should monitor both parties' regulatory filings and any subsequent court activity for further signals.
Orphalan v Novitium — key questions answered
Orphalan SA asserted two US patents: US10988436B2 (application no. 16/917266) and US11072577B2 (application no. 17/171358). Both patents relate to CUVRIOR® trientine tetrachloride tablets, 300 mg, a treatment for Wilson's disease. The suit was filed in the District of Delaware on September 29, 2023.
Orphalan filed a notice of voluntary dismissal pursuant to Rule 41(a)(1)(A) of the Federal Rules of Civil Procedure, noting that Novitium had not yet served an answer or dispositive motion. This made unilateral dismissal available as of right. The specific reasons driving the decision to dismiss are not disclosed in the available public record.
No. A dismissal without prejudice does not bar Orphalan from re-filing the same claims. No judgment on the merits was entered, and no estoppel arises from this dismissal. Both US10988436B2 and US11072577B2 remain in force and Orphalan retains full rights to assert them again in future proceedings.
CUVRIOR® is a brand-name pharmaceutical product containing trientine tetrachloride at a 300 mg tablet dosage form, used in the treatment of Wilson's disease — a rare genetic condition involving abnormal copper metabolism. US10988436B2 and US11072577B2 are the two patents Orphalan asserted in this action as covering aspects of this product. The precise claim scope of each patent is not summarised in the case record.
The case lasted 63 days from filing (September 29, 2023) to closure (December 1, 2023), ending before Novitium filed any answer or dispositive motion. Such a short duration, consistent with cases where parties resolve commercial matters outside the formal litigation record, suggests early-stage strategic recalibration — though the specific reasons are not disclosed in the available public record.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.